vs
ANI PHARMACEUTICALS INC（ANIP）とProto Labs Inc（PRLB）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $139.3M、Proto Labs Incの約1.8倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 5.8%、差は5.3%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 10.4%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 5.3%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Proto Labsは各種業界向けに迅速な部品製造サービスを提供する企業です。3Dプリント、CNC加工、板金加工、射出成形により、試作開発から量産まで対応可能なオーダーメイド部品を生産します。製品は医療機器、航空宇宙、電子機器、家電、自動車、消費財など多様な分野で活用されており、本社は米国ミネソタ州にあり、米国内各地に生産拠点を擁しています。
ANIP vs PRLB — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $139.3M |
| 純利益 | $27.5M | $8.1M |
| 粗利率 | — | 45.6% |
| 営業利益率 | 14.1% | 7.1% |
| 純利益率 | 11.1% | 5.8% |
| 売上前年比 | 29.6% | 10.4% |
| 純利益前年比 | 367.5% | 125.4% |
| EPS（希薄化後） | $1.14 | $0.29 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $139.3M | ||
| Q4 25 | $247.1M | $136.5M | ||
| Q3 25 | $227.8M | $135.4M | ||
| Q2 25 | $211.4M | $135.1M | ||
| Q1 25 | $197.1M | $126.2M | ||
| Q4 24 | $190.6M | $121.8M | ||
| Q3 24 | $148.3M | $125.6M | ||
| Q2 24 | $138.0M | $125.6M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $7.2M | ||
| Q2 25 | $8.5M | $4.4M | ||
| Q1 25 | $15.7M | $3.6M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $7.2M | ||
| Q2 24 | $-2.3M | $4.5M |
| Q1 26 | — | 45.6% | ||
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 45.3% | ||
| Q2 25 | — | 44.3% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 45.0% |
| Q1 26 | — | 7.1% | ||
| Q4 25 | 14.1% | 5.0% | ||
| Q3 25 | 15.9% | 6.5% | ||
| Q2 25 | 6.6% | 3.7% | ||
| Q1 25 | 13.3% | 3.6% | ||
| Q4 24 | -2.3% | -1.2% | ||
| Q3 24 | -13.8% | 6.8% | ||
| Q2 24 | 3.7% | 4.8% |
| Q1 26 | — | 5.8% | ||
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 5.3% | ||
| Q2 25 | 4.0% | 3.3% | ||
| Q1 25 | 8.0% | 2.9% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 5.7% | ||
| Q2 24 | -1.7% | 3.6% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $1.14 | $0.25 | ||
| Q3 25 | $1.13 | $0.30 | ||
| Q2 25 | $0.36 | $0.18 | ||
| Q1 25 | $0.69 | $0.15 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $-1.27 | $0.29 | ||
| Q2 24 | $-0.14 | $0.18 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $124.0M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $683.1M |
| 総資産 | $1.4B | $778.6M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $124.0M | ||
| Q4 25 | $285.6M | $128.1M | ||
| Q3 25 | $262.6M | $119.2M | ||
| Q2 25 | $217.8M | $103.2M | ||
| Q1 25 | $149.8M | $96.8M | ||
| Q4 24 | $144.9M | $103.1M | ||
| Q3 24 | $145.0M | $100.5M | ||
| Q2 24 | $240.1M | $112.9M |
| Q1 26 | — | $683.1M | ||
| Q4 25 | $540.7M | $673.9M | ||
| Q3 25 | $505.8M | $664.7M | ||
| Q2 25 | $436.8M | $664.7M | ||
| Q1 25 | $418.6M | $656.8M | ||
| Q4 24 | $403.7M | $670.2M | ||
| Q3 24 | $405.9M | $680.0M | ||
| Q2 24 | $455.8M | $685.2M |
| Q1 26 | — | $778.6M | ||
| Q4 25 | $1.4B | $763.4M | ||
| Q3 25 | $1.4B | $756.9M | ||
| Q2 25 | $1.3B | $743.3M | ||
| Q1 25 | $1.3B | $737.5M | ||
| Q4 24 | $1.3B | $743.5M | ||
| Q3 24 | $1.3B | $753.8M | ||
| Q2 24 | $920.8M | $758.2M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $17.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.16× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $17.5M | ||
| Q4 25 | $30.4M | $16.5M | ||
| Q3 25 | $44.1M | $29.1M | ||
| Q2 25 | $75.8M | $10.6M | ||
| Q1 25 | $35.0M | $18.4M | ||
| Q4 24 | $15.9M | $17.3M | ||
| Q3 24 | $12.5M | $24.8M | ||
| Q2 24 | $17.4M | $14.4M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $8.4M | ||
| Q3 25 | $38.0M | $25.0M | ||
| Q2 25 | $71.8M | $9.1M | ||
| Q1 25 | $32.5M | $17.1M | ||
| Q4 24 | $13.5M | $16.5M | ||
| Q3 24 | $7.7M | $23.2M | ||
| Q2 24 | $13.0M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 16.7% | 18.5% | ||
| Q2 25 | 34.0% | 6.7% | ||
| Q1 25 | 16.5% | 13.6% | ||
| Q4 24 | 7.1% | 13.5% | ||
| Q3 24 | 5.2% | 18.5% | ||
| Q2 24 | 9.4% | 8.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 5.9% | ||
| Q3 25 | 2.7% | 3.0% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 3.2% | 3.3% |
| Q1 26 | — | 2.16× | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 4.03× | ||
| Q2 25 | 8.87× | 2.39× | ||
| Q1 25 | 2.23× | 5.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | — | 3.18× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
